Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2005
Business Overview: The Company operates two primary segments: CooperVision (CVI), a global manufacturer of contact lenses, and CooperSurgical (CSI), a manufacturer of medical devices for women's healthcare. The reporting period is significantly impacted by the acquisition of Ocular Sciences, Inc. (Ocular) on January 6, 2005, for approximately $1.2 billion in cash and stock.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Net Sales | $147.9 million | $109.7 million |
| Gross Profit | $92.3 million | $70.0 million |
| Gross Margin | 62.4% | 63.8% |
| Operating Income | $27.7 million | $24.8 million |
| Net Income | $18.5 million | $18.4 million |
| Diluted EPS | $0.48 | $0.52 |
| Operating Cash Flow | $36.7 million | $6.8 million |
| Total Debt | $744.8 million | $165.7 million |
| Cash and Equivalents | $28.5 million | $39.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 35% year-over-year, driven primarily by the inclusion of Ocular Sciences' results post-acquisition. CVI sales grew 39% and CSI sales grew 17%.
- Profitability: While operating income rose 11% to $27.7 million, diluted earnings per share declined 8% to $0.48 due to a 9% increase in the weighted average number of shares outstanding from the stock issuance for the Ocular acquisition.
- Balance Sheet Expansion: Total assets more than doubled from $811.6 million to $2.1 billion, and total debt increased from $165.7 million to $744.8 million to fund the acquisition. Goodwill increased by approximately $985 million.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 39% to $60.2 million, and interest expense surged 149% to $3.7 million due to the new $750 million credit facility.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects fiscal year 2005 capital expenditures to range between $120 million and $130 million, with 70% allocated to manufacturing capacity expansion.
- Liquidity: The Company maintains $119 million in availability under its new KeyBank credit facility. Management believes operating cash flow and existing cash will fund operations, dividends, and smaller acquisitions.
- Interest Rate Risk: Following the acquisition, the Company entered into interest rate swaps with a notional value of $500 million to fix the rate on approximately 80% of its debt, mitigating exposure to variable rates.
- Legal Contingency: The Company is contesting a U.S. Tax Court deficiency notice from the IRS regarding Ocular's tax returns for 1999-2001, involving approximately $44.8 million in asserted taxes plus penalties. Management believes the outcome will not have a material adverse effect.
- Accounting Changes: The Company is preparing for the adoption of FASB Statement No. 123(R) regarding share-based payments, effective in the fourth fiscal quarter of 2005, which will require expensing stock options.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of integrating Ocular Sciences' operations and IT systems, as delays could impact internal controls and cost synergies.
- Debt Covenants: Monitor compliance with the new credit agreement covenants, specifically the debt-to-EBITDA ratio (currently 3.46:1) and the Senior Leverage Ratio (currently 2.93:1).
- Inventory Valuation: Review the $15 million one-time write-off of Ocular's inventory step-up and the timeline for its realization (approx. 7 months).
- Tax Litigation: Track the status of the IRS audit regarding Ocular's transfer pricing and potential liability exposure.
- EPS Dilution: Assess the long-term impact of the increased share count (approx. 10.7 million shares issued) on future earnings per share.